Viracta Therapeutics Inc VIRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VIRX is a good fit for your portfolio.
News
-
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
-
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
-
Thinking about buying stock in Quantum-Si, Victoria's Secret, Viracta Therapeutics, CERo Therapeutics, or Weyerhaeuser?
-
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
-
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trading Information
- Previous Close Price
- $0.85
- Day Range
- $0.82–0.85
- 52-Week Range
- $0.43–2.38
- Bid/Ask
- $0.75 / $0.89
- Market Cap
- $32.53 Mil
- Volume/Avg
- 36,928 / 118,083
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 40
- Website
- https://www.viracta.com
Financial Strength
|
Metric
|
VIRX
|
CELC
|
TGTX
|
|---|---|---|---|
Quick Ratio | 1.41 | 12.78 | 5.00 |
Current Ratio | 1.43 | 13.43 | 5.92 |
Interest Coverage | −13.69 | −12.43 | 2.04 |
Quick Ratio
VIRX
CELC
TGTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qrpbwmgb | Nglpp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qdcthgvlm | Dtdws | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rpnjmfpf | Dbydbsj | $97.8 Bil | |
MRNA
| Moderna Inc | Psjfnvvvn | Mcvz | $41.3 Bil | |
ARGX
| argenx SE ADR | Hgjpnlyg | Qfg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ggtrjhw | Jwy | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ynprpdvc | Jfkhf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wrvhjst | Hrpdnxg | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xmdfvytgw | Fzptq | $12.5 Bil | |
INCY
| Incyte Corp | Gvfhtgkf | Bdhhrnn | $11.6 Bil |